TNSN99090A1 - Agonistes et antagonistes selectifs de il-2 - Google Patents

Agonistes et antagonistes selectifs de il-2

Info

Publication number
TNSN99090A1
TNSN99090A1 TNTNSN99090A TNSN99090A TNSN99090A1 TN SN99090 A1 TNSN99090 A1 TN SN99090A1 TN TNSN99090 A TNTNSN99090 A TN TNSN99090A TN SN99090 A TNSN99090 A TN SN99090A TN SN99090 A1 TNSN99090 A1 TN SN99090A1
Authority
TN
Tunisia
Prior art keywords
cells
muteins
human
mutein
agonists
Prior art date
Application number
TNTNSN99090A
Other languages
English (en)
Inventor
Armen B Shanafelt
Jeffrey M Greve
Gary Jesmok
Kenneth J Lembach
Gayle D Wetzel
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of TNSN99090A1 publication Critical patent/TNSN99090A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'INVENTION CONCERNE UN POLYPEPTIDE COMPRENANT UNE MUTEINE DE IL-2 HUMAINE NUMEROTEE CONFORMEMENT A LA IL-2 DE TYPE SAUVAGE DANS LAQUELLE LADITE IL-2 HUMAINE EST SUBSTITUEE SUR AU MOINS L'UNE DES POSITIONS 20,88 ET 126 EN CONSEQUENCE DE QUOI LADITE MUTEINE ACTIVE DE FACON PREFERENTIELLE LES CELLULES T, PLUTOT QUE LES CELLULES TUEUSES NATURELLES. D20H ET I, N88G, I ET R, EN PARTICULIER, ONT UNE ACTIVITE DIFFERENTIELLE RELATIVE SUR LES CELLULES T BIEN SUPERIEURE A CELLE DE LA IL-2 NATIVE, AVEC UNE TOXICITE ASSOCIEE PREVUE REDUITE in vivo. L'INVENTION COMPREND AUSSI DES POLYNUCLEOTIDES CODANT LES MUTEINES DE L'INVENTION, DES VECTEURS CONTENANT LES POLYNUCLEOTIDES, DES CELLULES HOTES TRANSFORMEES, DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT LES MUTEINES, ET DES PROCEDES THERAPEUTIQUES DE TRAITEMENT.
TNTNSN99090A 1998-05-15 1999-05-13 Agonistes et antagonistes selectifs de il-2 TNSN99090A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
TNSN99090A1 true TNSN99090A1 (fr) 2005-11-10

Family

ID=22155135

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99090A TNSN99090A1 (fr) 1998-05-15 1999-05-13 Agonistes et antagonistes selectifs de il-2

Country Status (39)

Country Link
EP (1) EP1076704B1 (fr)
JP (1) JP4276783B2 (fr)
KR (1) KR100607609B1 (fr)
CN (2) CN101319247B (fr)
AR (1) AR020322A1 (fr)
AT (1) ATE351907T1 (fr)
AU (1) AU759697B2 (fr)
BG (1) BG65139B1 (fr)
BR (1) BRPI9910504B1 (fr)
CA (1) CA2327349C (fr)
CO (1) CO5070701A1 (fr)
CU (2) CU23273B7 (fr)
CY (1) CY1107533T1 (fr)
CZ (1) CZ302071B6 (fr)
DE (1) DE69934881T2 (fr)
DK (1) DK1076704T3 (fr)
DZ (1) DZ2788A1 (fr)
ES (1) ES2281175T3 (fr)
HK (1) HK1039963B (fr)
HN (1) HN1999000075A (fr)
HU (1) HU226142B1 (fr)
IL (2) IL139136A0 (fr)
MY (1) MY130274A (fr)
NO (1) NO329235B1 (fr)
NZ (1) NZ508098A (fr)
PA (1) PA8472601A1 (fr)
PE (1) PE20000475A1 (fr)
PL (1) PL201675B1 (fr)
PT (1) PT1076704E (fr)
RO (1) RO122150B1 (fr)
RU (1) RU2235729C2 (fr)
SI (1) SI20643B (fr)
SK (1) SK288100B6 (fr)
SV (1) SV1999000061A (fr)
TN (1) TNSN99090A1 (fr)
TR (1) TR200003354T2 (fr)
TW (1) TWI223663B (fr)
UA (1) UA73719C2 (fr)
WO (1) WO1999060128A1 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4057300A (en) * 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
EP1935431A3 (fr) 2000-05-15 2008-08-13 Health Research, Inc. Traitements anti-cancéreux utilisant une combinaison d'anticorps contre le HER2 et l'interleukine-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
WO2002079415A2 (fr) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
WO2005007121A2 (fr) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Polypeptides de l'interleukine-2(il-2) mutante
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
DK1944318T3 (da) 2003-07-21 2011-06-14 Transgene Sa Multifunktionelle cytokiner
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
JP5744369B2 (ja) * 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
BRPI0508470A (pt) * 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
WO2009061853A2 (fr) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Polypeptides d'interleukine-2 (il-2) mutants
CN101244261B (zh) * 2008-03-10 2010-09-15 山东大学 一种含未复性重组蛋白的生物制剂及其制备方法与应用
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
RS61854B1 (sr) 2010-11-12 2021-06-30 Nektar Therapeutics Konjugati il-2 dela i polimera
JP6093712B2 (ja) * 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
SI2673294T1 (sl) 2011-02-10 2016-08-31 Roche Glycart Ag Mutirani polipeptidi interlevkina-2
WO2012119093A1 (fr) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonistes et antagonistes de l'interleukine-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP2016533167A (ja) 2013-09-24 2016-10-27 メディシナ セラピューティクス ピーティーイー リミテッド インターロイキン−２融合タンパク質及びその使用
KR20190126205A (ko) 2014-02-06 2019-11-08 에프. 호프만-라 로슈 아게 인터류킨-2 융합 단백질 및 이의 용도
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3134102B1 (fr) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonistes, agonistes et antagonistes partiels de l'interleukine-2
JP6640834B2 (ja) * 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017201432A2 (fr) * 2016-05-19 2017-11-23 Jounaidi Youssef Interleukine-2 liée à son récepteur il-2rbêta, plate-forme pour améliorer l'activité des cellules tueuses naturelles et des lymphocytes t régulateurs
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2017220988A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anticorps multispécifiques pour l'immuno-oncologie
AU2017281469B2 (en) * 2016-06-22 2023-08-31 David Klatzmann Genetically modified T lymphocytes
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089420A1 (fr) 2016-11-08 2018-05-17 Delinia, Inc. Variants d'il-2 pour le traitement de maladies auto-immunes
US10472405B2 (en) * 2016-12-13 2019-11-12 Delinia, Inc. Multivalent regulatory T cell modulators
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
US12006354B2 (en) 2017-05-24 2024-06-11 Novartis Ag Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
US20200362058A1 (en) * 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
CN111201035A (zh) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
NZ761430A (en) * 2017-08-03 2024-03-22 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
EP3713592A4 (fr) * 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University Agonistes partiels de l'interleukine-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
CA3093722A1 (fr) 2018-03-28 2019-10-03 Ascendis Pharma Oncology Division A/S Conjugues d'il-2
WO2020007937A1 (fr) 2018-07-03 2020-01-09 Iltoo Pharma Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique
BR112021000811A8 (pt) * 2018-07-24 2022-10-18 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Agonistas de il2
EP3836954A1 (fr) 2018-08-13 2021-06-23 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
BR112020015030A2 (pt) * 2018-09-17 2021-03-16 Gi Innovation, Inc. Proteína de fusão compreendendo a proteína il-2 e a proteína cd80 e uso da mesma
KR20210107714A (ko) 2018-12-21 2021-09-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인간 인터류킨-2 변이체 또는 이의 유도체
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド ＭＡｄＣＡＭ標的化免疫寛容
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
CR20220111A (es) * 2019-08-13 2022-05-04 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras referencia cruzada a solicitudes relacionadas
JP2023505590A (ja) 2019-12-12 2023-02-09 イルトゥー・ファルマ インターロイキン２キメラ構築物
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions
WO2021168079A1 (fr) 2020-02-21 2021-08-26 Pandion Operations, Inc. Immunotolérance ciblée sur un tissu avec un effecteur cd39
CN115698052A (zh) 2020-03-19 2023-02-03 信达生物制药(苏州)有限公司 白介素2突变体及其用途
CA3169564A1 (fr) * 2020-03-31 2021-10-07 Hanmi Pharm. Co., Ltd. Nouveaux analogues d'il-2 immunostimulants
CA3178074A1 (fr) 2020-06-03 2021-12-09 Nina Gunnarsson Sequences d'il-2 et leurs utilisations
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
CA3195260A1 (fr) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Proteines de fusion pour le traitement d'une maladie
CN113308477A (zh) * 2021-04-08 2021-08-27 华南农业大学 一种鸭il-2基因真核表达重组质粒及其制备方法
WO2023045977A1 (fr) 2021-09-22 2023-03-30 信达生物制药(苏州)有限公司 Mutant de l'interleukine-2 et sa protéine de fusion
AU2022360645A1 (en) 2021-10-06 2024-05-02 Assistance Publique - Hôpitaux De Paris Interleukin 2 chimeric constructs with targeting specificity to inflamed tissues
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
TW202413442A (zh) * 2022-06-16 2024-04-01 美商希佛隆有限責任公司 抗pd-1抗體減弱之il-2免疫結合物及其用途
WO2024056154A1 (fr) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukine-2 pour le traitement des troubles du spectre autistique
FR3140287A1 (fr) 2022-10-03 2024-04-05 Arkema France Procede de granulation de composes azoiques et granules obtenus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
BR9910504A (pt) 2001-01-09
HUP0101948A2 (hu) 2001-09-28
HK1039963B (zh) 2008-09-05
HN1999000075A (es) 1999-09-29
EP1076704A1 (fr) 2001-02-21
SI20643B (sl) 2008-02-29
CA2327349A1 (fr) 1999-11-25
PL201675B1 (pl) 2009-04-30
BG65139B1 (bg) 2007-03-30
TR200003354T2 (tr) 2001-03-21
SK288100B6 (sk) 2013-07-02
PL344407A1 (en) 2001-11-05
EP1076704B1 (fr) 2007-01-17
CY1107533T1 (el) 2013-03-13
ATE351907T1 (de) 2007-02-15
HK1039963A1 (en) 2002-05-17
ES2281175T3 (es) 2007-09-16
SI20643A (sl) 2002-02-28
CN101319247B (zh) 2012-12-12
IL139136A0 (en) 2001-11-25
KR20010043602A (ko) 2001-05-25
KR100607609B1 (ko) 2006-08-02
NO20005762D0 (no) 2000-11-14
DE69934881T2 (de) 2007-11-08
NZ508098A (en) 2003-09-26
DZ2788A1 (fr) 2003-12-01
SK17242000A3 (sk) 2001-07-10
JP2002515247A (ja) 2002-05-28
RU2235729C2 (ru) 2004-09-10
CZ302071B6 (cs) 2010-09-29
AU759697B2 (en) 2003-04-17
MY130274A (en) 2007-06-29
CU23272A1 (es) 2008-04-09
WO1999060128A1 (fr) 1999-11-25
PA8472601A1 (es) 2000-09-29
DE69934881D1 (de) 2007-03-08
PE20000475A1 (es) 2000-07-07
CU23273B7 (es) 2008-04-09
CN101319247A (zh) 2008-12-10
TWI223663B (en) 2004-11-11
CN100366742C (zh) 2008-02-06
PT1076704E (pt) 2007-02-28
RO122150B1 (ro) 2009-01-30
BG104929A (en) 2001-09-28
DK1076704T3 (da) 2007-03-12
UA73719C2 (en) 2005-09-15
CA2327349C (fr) 2010-10-26
HUP0101948A3 (en) 2003-08-28
CZ20004213A3 (en) 2001-05-16
SV1999000061A (es) 2000-03-14
AU4078499A (en) 1999-12-06
AR020322A1 (es) 2002-05-08
NO329235B1 (no) 2010-09-20
HU226142B1 (en) 2008-05-28
BRPI9910504B1 (pt) 2016-08-09
CN1309705A (zh) 2001-08-22
IL139136A (en) 2009-05-04
JP4276783B2 (ja) 2009-06-10
CO5070701A1 (es) 2001-08-28
NO20005762L (no) 2001-01-11

Similar Documents

Publication Publication Date Title
TNSN99090A1 (fr) Agonistes et antagonistes selectifs de il-2
Kopke et al. Enhancing intrinsic cochlear stress defenses to reduce Noise‐Induced hearing loss
Landgren et al. Projection to cerebral cortex of group I muscle afferents from the cat's hind limb
Borghi et al. Vasoactive intestinal polypeptide (VIP) stimulates adenylate cyclase in selected areas of rat brain
Haufs et al. Psoriasis vulgaris treated successfully with mycophenolate mofetil
NO20010920L (no) Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder
IT1239281B (it) Composizioni per la riduzione dei depositi di grasso superfluo a base di principi attivi di origine vegetale ad attivita' agonista dell'adenilato ciclasi o/e ad attivita' antifosfodiesterasica
KR900005973A (ko) 사이클로스포린 안과용 조성물
ATE215381T1 (de) Pharmazeutische nichtinorganische salzlösungen für endonasale verabreichung eines calcitonins
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
Thomander et al. Motor fibre organization in the intratemporal portion of cat and rat facial nerve studied with the horseradish peroxidase technique
Mayevsky Level of ischemia and brain functions in the Mongolian gerbil in vivo
BR9007115A (pt) Novo trombolitico
Tyynelä et al. Congenital ovine neuronal ceroid lipofuscinosis—Acathepsin D deficiency with increased levels of the inactive enzyme
ES2171976T3 (es) Formulacion de ciclosporina.
UY27373A1 (es) Formulaciones de interferón beta-humano
HU205261B (en) Pharmaceutical compositions for treating primary cancer of pleura
DK0478631T3 (da) Målsøgende midler
Marengo-Rowe et al. New human haemoglobin variant from southern Arabia: G-Audhali (α23 (B4) Glutamic acid→ Valine) and the variability of B4 in human haemoglobin
Bicer et al. Effects of chronic oral amiodarone on left ventricular function, ECGs, serum chemistries, and exercise tolerance in healthy dogs
Piehslinger et al. Orthopedic jaw movement observations. Part III: The quantitation of mediotrusion
Sugiura et al. Regional differences in myosin heavy chain isoforms and enzyme activities of the rat diaphragm
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
DE69102174D1 (de) Iontophoresezusammensetzung zur Erhöhung der Hautkonzentration aktiver Wirkstoffe.